MedPath

Treatment of ekkushtha(psoriasis)by virechana karma and shiravedhan

Phase 2
Recruiting
Conditions
Patients suffereing from psoriasis
Registration Number
CTRI/2016/06/007035
Lead Sponsor
AYUSH department
Brief Summary

Inthis clinical trial total 64 patients were registered and randomly divided intotwo groups. In group A *Virechana karma* foll·        Inthis clinical trial total 64 patients were registered and randomly divided intotwo groups. In group A *Virechana karma* followedby *shaman yogas* and in group B *Virechana*followed by *Siravedhana Karma* and after that shaman yogas was given.Among them 28 patients were completed the treatment in group A and 30 patientswere completed the treatment in group B. 4 patients left before completion oftreatment in group A and 2 patients in group B. After completion of treatment patientsGroupAshowshighly significant(p<0.001) decrease in *Mandala* (Erythema) by 59.14%, *Matsyashakalopama*(Scaling) by 51.78%, *Rukshata* (Dryness) by 54.25%, *Aswedana* (Anhydrosis)by 58.1%, *Daha* (Burning sensation) by 56.67%, *Bahalatva* (Thickeningof skin lesion) by 47.36%, *Kandu* (Itching) by 56.00%, *Srava*(discharge) by 54.56%, DermatologyLife Quality Index (DLQI) by 56.57% and Psoriasis Area Severity Index (PASI)score by 52.28% and in group B alsoshows highly significant (p<0.001) decrease the *Mandala* (Erythema)by 65.9%, *Matsyashakalopama* (Scaling) by 63.67%, *Rukshata* (Dryness)by 60.24%, *Aswedana* (Anhydrosis) by 55.56%, *Daha* (Burningsensation) by 65.35%, *Bahalatva* (Thickening of skin lesion) by 56.84%, *Kandu*(Itching) by 65.51%, *Srava*( discharge) by 76.92% Dermatology Life Quality Index(DLQI) by 62.24% and Psoriasis Area Severity Index (PASI) score by 55.19%.

In Overall Effect of Therapy Marked improvement was found in 3(10.00%) patients ingroup B and 1(3.57%) patients in Group A. Moderate improvement was found in 20(66.66%) patients in Group B and 17 (60.71%) patient in Group A.

Inthe present study When Chi square– test was applied for comparison betweentwo groups there was not any significant difference found between two groups Howeverpercent wise group B showed better results.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients with all forms of Ekakushtha (Psoriasis) who are clinically fit to undergo Virechana and Shiravedhana.

Exclusion Criteria
  • Patients who are clinically unfit for Virechana and Shiravedhana Age 16yrs & 60yrs.
  • Pregnant women Uncontrolled Diabetes Mellitus & Hypertension Any other serious systemic illness Chronicity more than 10 years Patients who are not willing to be included in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relief in signs and symptoms of psoriasisafter 2 month of completion of treatment
Secondary Outcome Measures
NameTimeMethod
Efficacy and Safetyafter completion of 2 month of treatment

Trial Locations

Locations (1)

hospital of IPGT AND RA panchkarama department opd no 22

🇮🇳

Jamnagar, GUJARAT, India

hospital of IPGT AND RA panchkarama department opd no 22
🇮🇳Jamnagar, GUJARAT, India
Drjayesh odedra
Principal investigator
9429563141
drjayeshodedra@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.